雾化气管内给予多尼酶α治疗SARS-CoV-2所致ARDS的随机对照试验方案结构化摘要
COVIDornase试验是一项前瞻性、随机、对照、2臂(1:1)、多中心、开放标签临床试验,计划纳入100例机械通气的COVID-19相关ARDS患者,评估雾化气管内给予多尼酶α对ARDS严重程度和进展的影响。主要结局是D0至D7期间ARDS严重程度(Berlin标准)至少改善一个等级。
要点
- 多尼酶α可能分解细胞外DNA,减轻NETs诱导的肺泡损伤。
- 主要结局为D0至D7 ARDS严重程度至少改善一个等级。
- 计划纳入100例,1:1随机,中期分析20例。
核心结论
- 多尼酶α可能通过分解细胞外DNA减轻NETs毒性,改善COVID-19相关ARDS的严重程度和进展。
研究设计与样本
- COVIDornase为前瞻性、随机、对照、2臂(1:1)、多中心、开放标签临床试验。
- 计划随机100例机械通气的COVID-19相关ARDS患者,每组50例。
主要发现
- 主要结局为D0至D7期间ARDS严重程度(Berlin标准)至少一个等级改善,例如从重度到中度或从中度到轻度。
关键数值与推荐
- 纳入标准:年龄≥18岁,ICU住院,符合Berlin标准的ARDS(PaO2/FiO2<300且PEEP>5 cmH2O),插管<8天,预期机械通气>48小时,有动脉导管,前24小时有4个PaO2/FiO2值。
- 排除标准:对多尼酶α或其辅料过敏,妊娠或哺乳,受法律保护的患者。
- 干预:多尼酶α 2500 IU每日两次,间隔12小时,雾化吸入,连续7天,使用振动网孔雾化器。
- 对照组接受常规治疗,不使用雾化药物。
临床怎么用
- 多尼酶α可能使肺黏液变稀,促进分泌物清除,减少细胞外双链DNA诱导的肺泡过度炎症。
局限性
- 开放标签设计,参与者和护理人员不设盲,仅结局评估者设盲。
- 样本量较小(100例),中期分析计划在纳入20例时进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for the treatment of cystic fibrosis, which cleaves extracellular DNA and may break up cell-free DNA, loosening sticky mucus in the distal airways and reducing NETs-induced toxicity on alveolar pneumocytes. The COVIDornase trial intends to define the impact of aerosolized intra-tracheal dornase alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs. TRIAL DESIGN: COVIDornase is a prospective, randomized, controlled, 2-arm (1:1 ratio), multicentric, open-label clinical trial. PARTICIPANTS: The study will recruit mechanically ventilated patients hospitalized in the intensive care unit (ICU) in the recruiting centres (at the time of writing: The Rothschild foundation hospital in Paris, the Strasbourg university hospitals, and Metz-Thionville hospital) who have been diagnosed with COVID-19 and meet ARDS criteria. INCLUSION CRITERIA: - Adult patient (age ≥ 18 years old); - Hospitalized in ICU; - With severe COVID-19 pneumonia and ARDS according to Berlin criteria (PaO2/FiO2 < 300 and PEEP > 5 cmH2O); - Intubated for less than 8 days; - With an anticipated duration of mechanical ventilation > 48 hours; - Carrier of an arterial catheter; - For whom 4 PaO2/FiO2 values over the preceding 24 hours are available; NON-INCLUSION CRITERIA: - Known hypersensitivity to dornase alfa or any of its excipients; - Pregnant or breastfeeding status; - Patient under legal protection. INTERVENTION AND COMPARATOR: Intervention 1, Study group Dornase alfa (Pulmozyme®, Roche, Switzerland) will be administered by aerosol, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer (Aerogen Solo®, Aerogen, Ireland). The remainder of the management will be performed in accordance with good clinical practice, including mechanical ventilation (protective ventilation, PEEP > 5 cmH2O, tracheal balloon pressure check every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure < 30 cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2 < 150, early enteral nutrition, glycemic control and a sedation protocol based on the RASS score. Intervention 2, Comparator Patients will receive usual care in accordance with good practice (as detailed above), without aerosols. MAIN OUTCOMES: The primary outcome is the occurrence of at least one grade improvement between D0 (inclusion) and D7 in the ARDS scale severity (Berlin criteria). For instance from "severe" to "moderate" or from "moderate" to "mild". RANDOMISATION: All consecutive patients meeting the inclusion criteria will be randomised 1:1 using an eCRF-based, computer-generated randomisation table, either to the dornase alfa arm or to the control arm. An interim analysis will be performed after inclusion of 20 patients. Inclusions may be stopped at the interim analysis per data safety and monitoring board (DSMB) advice, if statistical analyses conclude on the futility or efficacy of the intervention or by other DSMB decision. BLINDING (MASKING): The participants and caregivers will not be blinded to study group assignment. Those assessing the outcomes will be blinded to study group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Fifty patients will be randomized to each group, 100 patients in total. TRIAL STATUS: Protocol version number 2, April 29th, 2020. Recruitment is ongoing. The trial started recruitment on the 21st April 2020. We estimate recruitment will finish August 21st 2020. TRIAL REGISTRATION: The trial was registered in ClinicalTrials.gov on 21 April 2020, updated on 8 May 2020. Trial registration number is NCT04355364. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated. This Letter serves as a summary of the key elements of the full protocol.
引用
- Desilles JP, Gregoire C, Le Cossec C, et al. Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32560746. doi:10.1186/s13063-020-04488-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。